SG161286A1 - Methods for treating and preventing fibrosis by il-21 / il-21r antagonists - Google Patents

Methods for treating and preventing fibrosis by il-21 / il-21r antagonists

Info

Publication number
SG161286A1
SG161286A1 SG201002668-0A SG2010026680A SG161286A1 SG 161286 A1 SG161286 A1 SG 161286A1 SG 2010026680 A SG2010026680 A SG 2010026680A SG 161286 A1 SG161286 A1 SG 161286A1
Authority
SG
Singapore
Prior art keywords
level
fibrosis
methods
treating
antagonists
Prior art date
Application number
SG201002668-0A
Other languages
English (en)
Inventor
Deborah A Young
Thomas A Wynn
Mary Collins
Michael Grusby
Original Assignee
Wyeth Corp
Us Gov Health & Human Serv
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36741387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG161286(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp, Us Gov Health & Human Serv, Harvard College filed Critical Wyeth Corp
Publication of SG161286A1 publication Critical patent/SG161286A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG201002668-0A 2005-04-14 2006-04-13 Methods for treating and preventing fibrosis by il-21 / il-21r antagonists SG161286A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67137405P 2005-04-14 2005-04-14

Publications (1)

Publication Number Publication Date
SG161286A1 true SG161286A1 (en) 2010-05-27

Family

ID=36741387

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201002668-0A SG161286A1 (en) 2005-04-14 2006-04-13 Methods for treating and preventing fibrosis by il-21 / il-21r antagonists

Country Status (22)

Country Link
US (2) US7910105B2 (fr)
EP (2) EP2436695A1 (fr)
JP (1) JP2008538553A (fr)
KR (1) KR20080017009A (fr)
CN (1) CN101287759A (fr)
AR (1) AR057274A1 (fr)
AU (1) AU2006236755A1 (fr)
BR (1) BRPI0609762A2 (fr)
CA (1) CA2604604A1 (fr)
CR (1) CR9428A (fr)
GT (1) GT200600148A (fr)
IL (1) IL186599A0 (fr)
MX (1) MX2007012842A (fr)
NI (1) NI200700259A (fr)
NO (1) NO20075193L (fr)
NZ (1) NZ562333A (fr)
PE (1) PE20070316A1 (fr)
RU (1) RU2419450C2 (fr)
SG (1) SG161286A1 (fr)
TW (1) TW200716171A (fr)
WO (1) WO2006113331A1 (fr)
ZA (1) ZA200708756B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2004007682A2 (fr) * 2002-07-15 2004-01-22 Wyeth Techniques et compositions permettant de moduler la fonction et le developpement de cellules assistantes (th)
RU2005131852A (ru) 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
CN1849131A (zh) * 2003-03-21 2006-10-18 Wyeth公司 用白介素－21/白介素－21受体的激动剂治疗免疫性疾病
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
EP1773394A2 (fr) * 2004-08-05 2007-04-18 Wyeth a Corporation of the State of Delaware Inhibition de l'activite du recepteur d'interleukine 21
ES2614735T3 (es) * 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
WO2009047360A1 (fr) * 2007-10-11 2009-04-16 Novo Nordisk A/S Anticorps il-21
CN102149403A (zh) * 2008-05-23 2011-08-10 惠氏有限责任公司 利用白介素-21受体结合蛋白的治疗方法
PE20100141A1 (es) * 2008-05-23 2010-02-22 Wyeth Corp Proteina de union al receptor de interleuquina 21
US9107942B2 (en) 2008-10-31 2015-08-18 University Of Rochester Methods of diagnosing and treating fibrosis
WO2011050263A2 (fr) * 2009-10-23 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunosuppression systémique dans le traitement de la dégénération maculaire liée à l'âge et de la rétinopathie diabétique
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
CN102532320A (zh) * 2012-03-06 2012-07-04 中国药科大学 全人源的抗人白介素21受体的单链抗体及其应用
ES2784234T3 (es) * 2013-10-08 2020-09-23 Promedior Inc Métodos para el tratamiento de cánceres fibróticos
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
WO2015110930A1 (fr) * 2014-01-24 2015-07-30 Pfizer Inc. Protéines de récepteur d'interleukine 21 modifiées
KR101756417B1 (ko) 2014-08-21 2017-07-10 한국유나이티드제약 주식회사 금제제를 포함하는 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물
CN108350032A (zh) 2015-10-09 2018-07-31 比奥尼斯有限责任公司 调节γC-细胞因子活性
US10301287B2 (en) 2016-08-31 2019-05-28 Tobira Therapeutics, Inc. Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
WO2019221576A1 (fr) * 2018-05-17 2019-11-21 광주과학기술원 Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1988007089A1 (fr) * 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
CA2140638C (fr) 1992-07-24 2010-05-04 Raju Kucherlapati Production d'anticorps xenogeniques
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5399677A (en) 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
SI9720020B (en) 1996-02-09 2001-12-31 Basf Ag Human antibodies that bind human TNF alpha
US6350892B1 (en) 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
ATE377076T1 (de) 1999-03-09 2007-11-15 Zymogenetics Inc Humanes cytokin als ligand des zalpha rezeptors und dessen verwendungen
IL145134A0 (en) 1999-03-25 2002-06-30 Knoll Gmbh Human antibodies that bind human il-12 and methods for producing
BR0107862A (pt) 2000-01-27 2002-11-05 American Cyanamid Co Método para a preparação de derivados do ácido alfa-sulfonil hidroxâmico
DE60125543T2 (de) * 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
AU6308801A (en) 2000-05-11 2001-11-20 Genetics Inst Mu-1, member of the cytokine receptor family
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
EP1432431B1 (fr) * 2001-10-04 2017-05-10 Genetics Institute LLC Procedes et compositions permettant de moduler l'activite de l'interleukine-21
AU2002336676A1 (en) * 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
WO2003087320A2 (fr) 2002-04-09 2003-10-23 Beth Israel Deaconess Medical Center, Inc. Antagonistes de il-21 et modulation des reponses des lymphocytes t induites par il-21
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
PT1531850E (pt) * 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
WO2004007682A2 (fr) * 2002-07-15 2004-01-22 Wyeth Techniques et compositions permettant de moduler la fonction et le developpement de cellules assistantes (th)
RU2005131852A (ru) * 2003-03-14 2006-04-20 Уайт (Us) Антитела против человеческого рецептора il-21 и их применение
CN1849131A (zh) * 2003-03-21 2006-10-18 Wyeth公司 用白介素－21/白介素－21受体的激动剂治疗免疫性疾病
EP1670501A2 (fr) 2003-09-25 2006-06-21 ZymoGenetics, Inc. Procedes de traitement de maladies auto-immunes utilisant l'interleukine-21
US20060024268A1 (en) * 2004-05-19 2006-02-02 Wyeth Modulation of immunoglobulin production and atopic disorders
EP1773394A2 (fr) 2004-08-05 2007-04-18 Wyeth a Corporation of the State of Delaware Inhibition de l'activite du recepteur d'interleukine 21
WO2009100035A2 (fr) 2008-02-01 2009-08-13 Wyeth Modulation de lymphocytes t régulateurs et forkhead box p3 (foxp3) par des modulateurs de l’interleukine-21 (il-21) et du récepteur de l’il-21 (il-21r)
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
CA2604604A1 (fr) 2006-10-26
NO20075193L (no) 2008-01-11
AR057274A1 (es) 2007-11-28
RU2419450C2 (ru) 2011-05-27
CR9428A (es) 2008-02-20
ZA200708756B (en) 2008-09-25
NI200700259A (es) 2009-03-03
EP1871800A1 (fr) 2008-01-02
WO2006113331A1 (fr) 2006-10-26
NZ562333A (en) 2011-04-29
IL186599A0 (en) 2008-01-20
JP2008538553A (ja) 2008-10-30
PE20070316A1 (es) 2007-04-16
RU2007138011A (ru) 2009-05-20
TW200716171A (en) 2007-05-01
US20060257403A1 (en) 2006-11-16
AU2006236755A1 (en) 2006-10-26
EP2436695A1 (fr) 2012-04-04
US20110142833A1 (en) 2011-06-16
GT200600148A (es) 2006-11-22
BRPI0609762A2 (pt) 2010-04-27
CN101287759A (zh) 2008-10-15
US7910105B2 (en) 2011-03-22
MX2007012842A (es) 2007-11-20
KR20080017009A (ko) 2008-02-25

Similar Documents

Publication Publication Date Title
SG161286A1 (en) Methods for treating and preventing fibrosis by il-21 / il-21r antagonists
GB0317466D0 (en) Use
WO2007067946A3 (fr) Diagnostic et traitement de la leucemie lymphoide chronique (llc)
IN2012DN06588A (fr)
WO2008060813A3 (fr) Anticorps antagonistes de haute affinité dirigés contre le récepteur alpha 1 de l'interleukine-13
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
WO2006009629A3 (fr) Procedes et agents permettant de conserver la masse musculaire et d'empecher une atrophie musculaire et des biomarqueurs de surveillance associes
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
DE60207514D1 (de) Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten
SI1730315T1 (sl) Polimorfizmi v genu NOD2/CARD15
IL166466A0 (en) Methods for the treatment of dementia based on apoe genotype
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
WO2007134028A3 (fr) Biomarqueurs pour la dépression et méthodes d'utilisation de ceux-ci
ATE405670T1 (de) Autoimmunerkrankungen und nadph-oxidase-defekte
WO2004081229A3 (fr) Compositions a activite hematopoietique et immunitaire
WO2008079877A3 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des troubles associés au fer
WO2007076240A3 (fr) Compositions et procedes de dosage d'absorption de lipoproteines
WO2005044293A3 (fr) Compositions pouvant empecher des troubles neurodegeneratifs et procede pour tester l'activite de telles compositions
WO2006089009A8 (fr) Procedes et compositions pour le traitement de troubles associes aux lipides
WO2009029587A3 (fr) Compositions et procédés pour le diagnostic et le traitement d'une dégénérescence maculaire
WO2007005443A3 (fr) Methodes therapeutiques faisant intervenir des inhibiteurs du pai-1 et des animaux non humains transgeniques pour le criblage d'inhibiteurs du pai-1 candidats
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
WO2002098278A3 (fr) Voie de differenciation de fibrocytes sanguins peripheriques et migration vers des sites leses
WO2007005987A3 (fr) Procedes et compositions pour traiter des maladies ayant pour cible maba1
WO2006034485A3 (fr) Traitement du declin cognitif et d'autres etats lies a l'age